219 related articles for article (PubMed ID: 23125419)
1. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
Tager AM
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419
[No Abstract] [Full Text] [Related]
2. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
4. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
5. Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis.
Gotoh M; Fujiwara Y; Yue J; Liu J; Lee S; Fells J; Uchiyama A; Murakami-Murofushi K; Kennel S; Wall J; Patil R; Gupte R; Balazs L; Miller DD; Tigyi GJ
Biochem Soc Trans; 2012 Feb; 40(1):31-6. PubMed ID: 22260662
[TBL] [Abstract][Full Text] [Related]
6. Chemical evolution of autotaxin inhibitors.
Albers HM; Ovaa H
Chem Rev; 2012 May; 112(5):2593-603. PubMed ID: 22335786
[No Abstract] [Full Text] [Related]
7. Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Taneja A; Desrivot J; Diderichsen PM; Blanqué R; Allamasey L; Fagard L; Fieuw A; Van der Aar E; Namour F
Clin Pharmacokinet; 2019 Sep; 58(9):1175-1191. PubMed ID: 30953319
[TBL] [Abstract][Full Text] [Related]
8. Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry.
Cuozzo JW; Clark MA; Keefe AD; Kohlmann A; Mulvihill M; Ni H; Renzetti LM; Resnicow DI; Ruebsam F; Sigel EA; Thomson HA; Wang C; Xie Z; Zhang Y
J Med Chem; 2020 Jul; 63(14):7840-7856. PubMed ID: 32584034
[TBL] [Abstract][Full Text] [Related]
9. Autotaxin and Lysophosphatidic Acid Signalling: the Pleiotropic Regulatory Network in Cancer.
Vít O; Petrák J
Folia Biol (Praha); 2023; 69(5-6):149-162. PubMed ID: 38583176
[TBL] [Abstract][Full Text] [Related]
10. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin in liver fibrosis.
Ikeda H; Yatomi Y
Clin Chim Acta; 2012 Nov; 413(23-24):1817-21. PubMed ID: 22820036
[TBL] [Abstract][Full Text] [Related]
12. The autotaxin-lysophosphatidic acid pathway in pathogenesis of rheumatoid arthritis.
Orosa B; García S; Conde C
Eur J Pharmacol; 2015 Oct; 765():228-33. PubMed ID: 26297977
[TBL] [Abstract][Full Text] [Related]
13. An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.
Castelino FV; Bain G; Pace VA; Black KE; George L; Probst CK; Goulet L; Lafyatis R; Tager AM
Arthritis Rheumatol; 2016 Dec; 68(12):2964-2974. PubMed ID: 27390295
[TBL] [Abstract][Full Text] [Related]
14. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
15. Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target.
Ntatsoulis K; Karampitsakos T; Tsitoura E; Stylianaki EA; Matralis AN; Tzouvelekis A; Antoniou K; Aidinis V
Front Immunol; 2021; 12():687397. PubMed ID: 34671341
[TBL] [Abstract][Full Text] [Related]
16. First-in-class antifibrotic therapy targeting type 1 lysophosphatidic acid receptor.
Im DS
Arch Pharm Res; 2012 Jun; 35(6):945-8. PubMed ID: 22870802
[TBL] [Abstract][Full Text] [Related]
17. alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors.
Cui P; McCalmont WF; Tomsig JL; Lynch KR; Macdonald TL
Bioorg Med Chem; 2008 Mar; 16(5):2212-25. PubMed ID: 18082408
[TBL] [Abstract][Full Text] [Related]
18. The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiforme.
Tabuchi S
Lipids Health Dis; 2015 Jun; 14():56. PubMed ID: 26084470
[TBL] [Abstract][Full Text] [Related]
19. Enhancement and inhibition of snake venom phosphodiesterase activity by lysophospholipids.
Mamillapalli R; Haimovitz R; Ohad M; Shinitzky M
FEBS Lett; 1998 Oct; 436(2):256-8. PubMed ID: 9781690
[TBL] [Abstract][Full Text] [Related]
20. A 3D view of autotaxin.
Nishimasu H; Ishitani R; Aoki J; Nureki O
Trends Pharmacol Sci; 2012 Mar; 33(3):138-45. PubMed ID: 22277299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
